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IGPR-1 IS A NOVEL ADHESION MOLECULE INVOLVED IN COLORECTAL 
TUMOR GROWTH 
 
NICHOLAS TAYLOR WOOLF 
ABSTRACT 
 Colorectal cancer (CRC) is among the most prevalent and lethal cancers in the 
United States. The mechanisms by which tumor cells sense their microenvironment have 
profound importance in driving the progression of malignancy and evasion from 
treatment. Specialized microenvironment-sensing cell surface receptors such as cell 
adhesion molecules allow tumor cells to survey and respond to their microenvironment. 
We have recently identified a novel cell adhesion molecule named immunoglobulin-
containing and proline-rich receptor 1 (IGPR-1) that is normally expressed in both 
endothelial and epithelial human cell types; however, its potential role in human 
malignancy remains unknown. To investigate the role IGPR-1 plays in CRC tumor 
growth, we overexpressed IGPR-1 in human HT29 and HCT116 colon adenocarcinoma 
cells and examined the effect of IGPR-1 on tumor growth and the mechanisms involved 
in a cell culture system. The data demonstrate that overexpression of IGPR-1 enhances 
CRC cell proliferation and survival in vitro. Furthermore, we demonstrate that the 
extracellular domain of IGPR-1 is required for its ability to support tumor growth. While 
deletion of the extracellular domain of IGPR-1 impaired its ability to promote tumor cell 
survival, stimulation of the chimeric IGPR-1 consisting of the extracellular domain of 
human colony stimulating factor-1 receptor (CSF-1R) fused to the transmembrane and 
cytoplasmic domains of IGPR-1 promoted tumor cell survival. Additionally, the presence 
  viii 
of serine 186 and 220 in the cytoplasmic domain is important for IGPR-1 activity in 
tumor cells. This work identifies IGPR-1 as an important protein in the regulation of 
CRC cell growth and survival, and this makes it a possible therapeutic target in the 
clinical management of CRC.  
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INTRODUCTION 
Colorectal Cancer Epidemiology 
Colorectal cancer (CRC) is third highest among all cancers in terms of incidence 
and mortality in both men and women in the United States. CRC incidence and mortality 
rates have both dropped by 3% in the US during the past decade, especially in the adult 
population aged 65 and older (Siegel, et al. 2014). Unfortunately, this encouraging trend 
is not reflected worldwide, as CRC incidence rates have increased for both men and 
women in areas such as Eastern Europe, Asia and South America (Center, et al. 2009). 
This dichotomy in regional CRC incidence is partly due to recent economic and dietary 
changes, which have led to increased food intake and westernized food choices and 
portions in nations such as the Czech Republic, Slovakia and Japan (Center, et al. 2009). 
The high-calorie western diet and weight gain are both known risk factors for CRC 
(Hartz, et al. 2012 and Kasdagly, et al. 2014). Although more economically developed 
nations like the United States have similar dietary habits, they have also implemented and 
promoted colon cancer prevention measures for a longer period of time. These measures 
include regular fecal occult blood tests and colonoscopies in adult patients after age 50, 
and they have helped to save lives by identifying colon polyps at earlier, premalignant 
stages. Nevertheless, if CRC incidence and mortality rates are to be further reduced 
worldwide, more effective screening and treatment modalities are needed. 
Molecular Pathogenesis of Colorectal Cancer 
CRC Stem Cells 
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It is now widely recognized that many tumors, including colorectal adenomas, 
begin with genetic alterations in cells with stem-like characteristics. The changes in 
oncogenes or tumor-suppressor genes are then passed on as these cells divide and 
differentiate. In CRC, tumor-initiating changes affect multipotent stem cells that reside in 
the colonic crypts of Lieberkühn (van der Flier and Clevers 2009). These crypt stem cells 
are responsible for rapidly replenishing the epithelial cell layer that lines the colonic 
lumen. The cells can divide either symmetrically or asymmetrically; symmetrical division 
produces two differentiated daughter cells or two stem cells, while asymmetrical division 
produces one daughter cell and one stem cell. In this manner, a single stem cell can 
produce progeny that come to dominate the cell population of a specific crypt in a 
process called monoclonal conversion. This process and the eventual crypt fission that 
follows have been proposed as the mechanism by which a single mutation in a crypt stem 
cell can spread and produce an adenoma (Zeki, et al. 2011). These stem cells are also 
thought to play a crucial role in metastasis, since they would serve as the tumor-initiating 
cells after implantation in the secondary organ site (Brabletz, et al. 2005). Given CRC 
stem cells’ crucial importance in tumor progression, researchers and clinicians have 
sought to target them as part of the next generation of CRC detection and treatment 
strategies. 
Getting a reliable molecular phenotype for CRC stem cells has proven to be a 
difficult task, with various flow cytometry experiments returning multiple potential cell 
surface markers for CRC-initiating stem cells. In two separate studies, the authors found 
that human CRC-derived CD133+ cells (comprising just 2.5% of the tumor cell mass) 
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were the only cells able to reproduce the original tumor in immunodeficient mice, and 
they grew in an undifferentiated state for more than a year in vitro (O’Brien, et al. 2007 
and Ricci-Vitiani, et al. 2007). However, shortly after these findings were reported, 
another group found that a population of human CRC cells positive for epithelial cell 
adhesion molecule (EpCAM), CD44 and CD166 were the only cells capable of forming 
tumors when injected subcutaneously into NOD/SCID mice (Dalerba, et al. 2007). This 
study also found that CD133 expression was heterogeneous across multiple human CRC 
samples, which raises doubts about the previous authors’ findings. Still, it has also been 
reported that when tumors contain cells expressing CD133 and CD44 heterogeneously, 
only cells that express both of these molecules are able to form new tumors in mice 
(Haraguchi, et al. 2008 and Chen, et al. 2011). Further complicating matters, another 
recent study has suggested that a population of CD24+ stem cells should be targeted in 
CRC treatment strategies, since these cells are more likely to undergo epithelial-
mesenchymal transition (EMT) and metastasize (Okano, et al. 2014). Taken together, 
these studies paint an unclear picture regarding a universal molecular phenotype for the 
CRC stem cell, but several promising molecules have been identified that could be 
targeted by future CRC treatments. 
The CRC Tumorigenic Progression Pathway 
 The first of two major tumorigenic pathways in CRC involves initial dysfunction 
in the Wnt signaling pathway. Specifically, alterations in the tumor-suppressing molecule 
adenomatous polyposis coli (APC) are the first step in what is known as the classic 
pathway. APC is part of a complex that also includes glycogen synthase kinase 3β 
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(GSK3β), casein kinase 1 (CK1) and Axin. When the Wnt receptor is inactive, this 
complex sequesters a molecule called β-catenin and phosphorylates it, which targets it for 
proteasomal degradation. However, when Wnt ligands bind the Frizzled receptor, its co-
receptor low-density lipoprotein receptor-related protein 5/6 (LRP5/6) binds Axin and 
another molecule called disheveled (Dvl) binds GSK3β. These actions sequester key 
components of the destruction complex and render it inactive, allowing β-catenin to 
translocate to the nucleus and serve as a transcriptional co-activator with T cell factor 
(TCF) transcription factors. This leads to increased expression of several target genes, 
many of which promote increased cell growth and proliferation (van der Flier and 
Clevers 2009). 
The mutations in APC were originally discovered in patients with familial 
adenomatous polyposis (FAP), an autosomal dominant syndrome that leads to the 
formation of hundreds to thousands of individual colonic polyps and requires total 
colectomy early in life (Fearon 2011). While germline APC point or missense mutations 
account for a small percentage of colorectal tumors, around 80% of sporadic colorectal 
tumors originate with somatic APC mutations (Fearon 2011). Most of these mutations 
occur in the β-catenin-binding domain of APC and prevent proper phosphorylation and 
destruction of β-catenin. The resulting β-catenin accumulation in the cytoplasm 
eventually leads to an increase in nuclear β-catenin, which induces constitutive 
transcription of several oncogenes and results in unchecked cellular proliferation (Fearon 
2011). The high frequency of APC mutations in sporadic colorectal adenomas has 
resulted in APC being dubbed the “gatekeeper” molecule in the classic pathway of 
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colorectal tumorigenesis (Kwong and Dove 2009). APC dysfunction is an early step in 
this pathway because, while it does lead to the formation of tubular adenomas, other 
mutations are required to complete the classic colorectal adenoma-carcinoma sequence. 
 The subsequent gene mutations in the classic pathway increase the dysplastic 
nature of the colorectal adenoma until it becomes a carcinoma. Generally regarded as the 
second major mutated protein in the sequence, KRAS is a well-known upstream 
enzymatic effector of the pro-survival and pro-growth mitogen-activated protein kinase 
(MAPK) pathway. KRAS was one of the earliest genes identified as mutated in CRC via 
the restriction fragment length polymorphism (RFLP) technique (Vogelstein, et al. 1988). 
It is now known that this gene is subject to missense mutations at several codons, all of 
which promote constitutive KRAS activation by inhibiting its intrinsic GTPase function 
(Zoratto, et al. 2014). This allows the KRAS enzyme to stay bound to GTP and activate 
the MAPK pathway continuously, which leads to a marked increase in tumor size.  
Another important genetic alteration identified early on by RFLP is the loss of 
heterozygosity (LOH) at chromosome 18 (Vogelstein, et al. 1988). LOH results in 
chromosomal instability (CIN) in the q arm of chromosome 18 and deletion of key genes 
within this area of the chromosome, including deleted in colon cancer (DCC) (Zoratto, et 
al. 2014). Loss of DCC and other genes located on 18q (including tumor suppressors 
SMAD2 and SMAD4) speeds tumor progression by further promoting a state of genetic 
chaos in CRC cells (Grady and Markowitz 2002). CIN is the major epigenetic disruption 
of the classic CRC pathway, and it affects many chromosomal sites in addition to 18q. 
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One of the chromosomal sites that can be affected by CIN is 17p, which is home 
to the crucial gene TP53 (Fearon 2011). Mutation or loss of TP53 is the final step in the 
classic pathway of colorectal tumorigenesis. This gene produces the transcription factor 
p53, widely known as the “guardian of the genome” because it is responsible for ensuring 
the integrity of every cell’s DNA. Normally, when a cell’s DNA becomes irreversibly 
damaged, p53 expression increases and it activates transcription of pro-apoptotic genes 
(e.g. BAX) that promote cell death before any genomic errors are propagated via mitosis 
(Grady and Markowitz 2002). However, when TP53 is the victim of inactivating 
mutations, the corresponding p53 protein can no longer bind to its designated promoter 
regions and serve as an essential genomic watchdog. This enables a cascade of mutations 
and other genetic aberrations that lead to the onset of colorectal adenocarcinoma and 
eventual metastasis. 
The Alternative (Serrated) Tumorigenic Pathway 
 While the classic pathway gives rise to tubular adenomas, the alternative pathway 
produces serrated adenomas, which are so-named due to their jagged, tooth-like 
appearance. Serrated colorectal adenomas are the hallmark of an inherited syndrome 
called hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. It arises due to 
germline mutations of DNA mismatch repair genes such as hMSH2 and hMLH1, which 
causes widespread microsatellite instability (MSI) and CpG island methylation (Grady 
and Markowitz 2002). Microsatellites are DNA repeats that occur frequently throughout 
the genome and are usually made up of no more than six nucleotides. These areas of 
DNA are especially susceptible to DNA polymerase errors that result in base pair 
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mismatches (Zoratto, et al. 2014). When several mismatch repair genes are mutated, these 
errors go uncorrected and promote other gene mutations (Jass 2002). Sporadic tumors 
with MSI also tend to have a CpG island methylation phenotype (CIMP), where the 
transcription of tumor suppressor genes is negatively regulated via hypermethylation of 
CpG islands in their promoter regions (Jass 2002 and Fearon 2011). Tumor suppressor 
genes such as APC and TP53 are less commonly mutated in the serrated pathway; 
nevertheless, they are included in a broad number of genes that can be affected by MSI 
and CIMP. 
The serrated pathway is responsible for approximately 15% of sporadic CRC, and 
most of these cases involve both MSI and CIMP and have gain-of-function mutations of 
the BRAF oncogene (Grady and Markowitz 2002 and Fearon 2011). BRAF is an anti-
apoptotic serine/threonine kinase, and several activating mutations (including the well-
known V600E mutation) can result in its constitutive activity early in the alternative 
pathway’s sequence; it plays a significant role in the initial serration of the epithelial 
crypts (Zoratto, et al. 2014). Although the serrated pathway is not as common, its unique 
genetic disruptions should be kept in mind when devising CRC screening and treatment 
strategies. 
 The classic and alternative tumorigenic pathways have well-established molecular 
mechanisms, but their key genes and patterns of mutation have yet to be optimally 
leveraged for the benefit of CRC screening efforts in the United States. While 
colonoscopies have proven effective at identifying polyps, there is no cheap, effective 
screening test that looks at the status of any of the genes discussed above. With this in 
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mind, some clinicians have surmised that traits such as CpG methylation or TP53 
mutational status could be tested in future strategies (Davies, et al. 2005). While there are 
certainly technologies available to screen for these characteristics, clinical utility and 
financial concerns continue to prevent their adoption as a commonplace clinical test for 
CRC. 
Colorectal Cancer Metastasis 
 A cancer patient’s prognosis is worsened considerably once cells from the 
primary tumor metastasize and form secondary tumors at other locations in the body. 
Colorectal tumors, like all other solid tumors, gain the ability to invade and metastasize 
via an extraordinary phenotypic change known as the epithelial-mesenchymal transition 
(EMT) (Hanahan and Weinberg 2011). This process is marked by transcriptional 
repression of several epithelial cell markers including E-cadherin, a cell adhesion 
molecule that is essential for the formation of adherens junctions between neighboring 
cells (Onder, et al. 2008 and Polyak and Weinberg 2009). Loss of E-cadherin is 
significant not only because it allows cells to break free from the mass of other tumor 
cells, but also because it is associated with increased cell invasion and anchorage-
independent cell survival (Onder, et al. 2008 and Prindull and Zipori 2004). Expression 
of E-cadherin is inhibited by a transcription factor called Snail, which also acts to 
promote transcription of mesenchymal proteins such as vimentin. Overexpressing Snail 
in human CRC cells leads to increased motility and invasiveness, and it also increases 
expression of previously-mentioned cancer stem cell markers CD133 and CD44 (Fan, et 
al. 2012). This suggests that CRC cells undergoing EMT also gain a cancer stem cell 
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phenotype that allows them to survive in the circulation and become more 
chemoresistant. These cells must mimic a mesenchymal cell’s survival strategy in order 
to survive the arduous journey from the primary tumor, through the bloodstream and to a 
distant, secondary tumor site. 
Normally, cells that inappropriately break free from neighboring cells and the 
extracellular matrix (ECM) undergo a specific type of apoptosis called anoikis (Gilmore 
2005). Epithelial and endothelial cells are susceptible to anoikis because they are 
supposed to remain in close contact with other cells and the ECM; conversely, 
mesenchymal and hematopoietic cells are resistant to anoikis because they must be able 
to detach and migrate easily within their respective tissues (Gilmore 2005 and Taddei, et 
al. 2012). Loss of E-cadherin, among other changes that occur during the EMT, activates 
several pro-survival signaling pathways, including the PI3K/Akt and Ras/MAPK 
pathways (Guadamillas, et al. 2011 and Kim, et al. 2012). Specifically, CRC cells have 
demonstrated elevated expression of PI3K, especially in HT29 and SW480 cell lines 
(Wang, et al. 2003 and Wang, et al. 2013). An increase in these signaling molecules 
allows metastatic tumor cells to complete their mesenchymal mimicry, thus avoiding 
anoikis and surviving in the circulation. 
IGPR-1: A Novel Cell Adhesion Molecule 
 Our laboratory has previously identified a molecule named immunoglobulin-
containing and proline-rich receptor 1 (IGPR-1) as a novel cell adhesion molecule that 
regulates endothelial cell-cell interaction, cell migration and angiogenesis. IGPR-1 is 
expressed in higher mammalian species, including horses, cats, dogs, chimpanzees and 
 10 
humans, but it is not expressed in rats or mice. IGPR-1 is a 31 kDa protein and contains a 
single extracellular immunoglobulin domain, a transmembrane domain and a cytoplasmic 
region that is rich in proline residues (Rahimi, et al. 2012). When expressed in vitro, the 
observed molecular weight of IGPR-1 increases to 55 kDa, which is most likely due to 
glycosylation at multiple extracellular sites (Rahimi, et al. 2013). Of note, IGPR-1 is only 
expressed in endothelial and epithelial cell types. 
To determine the role IGPR-1 plays in angiogenesis, IGPR-1 was overexpressed 
in porcine aortic endothelial (PAE) cells. Overexpression resulted in an increase in 
capillary tube formation by these cells, which indicates that IGPR-1 promotes 
angiogenesis. IGPR-1 overexpression also led to a change in PAE cell morphology, an 
increase in actin filament formation, an increase in focal adhesion complexes and a 
decrease in cell motility (Rahimi, et al. 2012). These findings all support IGPR-1’s role 
as a pro-angiogenic cell-adhesion molecule in endothelial cells; however, the role it plays 
in diseases involving endothelial or epithelial cell pathology has not yet been elucidated. 
 A recent screen of cancer cell types in our laboratory demonstrated that IGPR-1 is 
expressed in various cancer types, including breast, lung and colorectal (unpublished 
data). Recently, we have also found that IGPR-1 is expressed heterogeneously in more 
than 100 colorectal tumor tissue samples taken from patients at Boston Medical Center 
(Figure 1). The overarching goal of this project was to determine the role of IGPR-1 in 
CRC growth and survival in an in vitro system and the mechanisms involved. Our 
findings demonstrate that IGPR-1 promotes colorectal tumor growth and survival in vitro 
only upon activation of its extracellular domain. 
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Figure 1: IGPR-1 is expressed in colorectal tissue. Immunohistochemical staining 
demonstrates expression of IGPR-1 in both normal colonic crypts (arrow) and 
adenomatous colonic tissue (arrowhead). Magnification= 40X.
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METHODS 
Cell Lines and Growth Conditions 
HEK293, HT29, HCT116 and B16F cell lines were purchased from ATCC 
(Manassas, VA). Cells were grown in 10 cm culture dishes (Corning, Corning, NY). 
Culture medium was Dulbecco’s Modification of Eagle’s Medium (DMEM) with 4.5 g/L 
glucose, L-glutamine and sodium pyruvate supplemented with 10% FBS and 
penicillin/streptomycin (Corning). To maintain expression of viral vectors in transduced 
cells, their media was supplemented with 1 µg/mL puromycin. 
Plasmids and Antibodies 
 IGPR-1, ΔN-IGPR-1, A220 IGPR-1 and A186 IGPR-1 cDNA constructs were 
cloned into retroviral vector pMSCV.puro as previously described (Rahimi, et al. 2012). 
cIGPR-1 plasmids were produced by cloning the extracellular domain of the CSF-1 
receptor and the transmembrane and cytoplasmic domains of IGPR-1 into retroviral 
vector pMSCV.puro in a procedure modeled after previous creation of chimeric VEGFR 
molecules (Rahimi, et al. 2000). 
 Polyclonal rabbit IGPR-1 antibody was produced as previously described 
(Rahimi, et al. 2012). Polyclonal rabbit PLCγ1 (sc-81) and monoclonal mouse Hsp70 (sc-
24) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Virus Production and Transduction 
 The pMSCV.puro vectors containing IGPR-1 constructs or empty vectors were 
transfected into 293-GPG cells, and viral supernatants were collected for 3 days as 
previously described (Rahimi, et al. 2000). Concentrated virus was transduced into HT29, 
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HCT116 and B16F cells by adding 3 mL of virus-containing DMEM and 10 µg of 
polybrene to cells in 6 cm culture dishes (Corning). After 16 hours, this media was 
removed and puromycin-supplemented DMEM was added to ensure survival of 
transduced cells only. 
Western Blotting 
 Whole-cell lysates were used for Western blot analysis as described previously 
(Meyer, et al. 2011). Briefly, whole-cell lysates normalized for protein content were 
subjected to SDS-PAGE and gel contents were transferred to PVDF membranes. 
Membranes were blocked in 2% milk solution and exposed to IGPR-1, PLCγ1 or Hsp70 
antibody as appropriate. Membranes were then incubated in either goat anti-rabbit (sc-
2004) or goat anti-mouse (sc-2055) horseradish peroxidase-conjugated secondary 
antibodies purchased from Santa Cruz Biotechnology. Protein bands were detected by an 
ECL system (EMD Millipore, Billerica, MA). 
MTT Cell Proliferation Assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell 
proliferation assay was performed as described previously (Mosmann 1983). 5x104 cells 
were plated in 400 µL of DMEM + 1% FBS in each well of a 24-well low attachment 
plate (Corning). Cells were distributed such that n=4 wells were used per cell 
type/treatment group (0, 10 and 50 ng CSF-1) per time point (0, 2 and 4 days). At each 
time point, 5 µL of MTT dye (Promega, Madison, WI) was added to each well, and 100 
µL of solubilization solution (Promega) was added after two hours of incubation at 37°C 
and 5% CO2. After an additional hour of incubation, 190 µL of solution from each well 
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was transferred to a 96-well plate (Corning) and read at an absorbance of 570 nm in a 
microplate reader (VERSA max, Molecular Devices, Sunnyvale, CA). The resulting data 
were used to generate percent survival curves, with day 0 values serving as 100% 
survival baselines. 
Statistical Analyses 
 The Student’s two-tailed t-test (assuming equal variances) was used to analyze 
cell survival data in experiments comparing two cell lines. For experiments that 
compared three or more cell lines, the one-way ANOVA with Tukey’s post-hoc test was 
used to analyze the results. An alpha value of P < 0.05 denoted a significant difference 
between two groups in all cell survival comparisons. T tests were performed using 
Microsoft Excel and ANOVA tests were performed online at http://www.vassarstats.net.  
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RESULTS 
IGPR-1 Activity Promotes Cancer Cell Survival 
Cell adhesion molecules play a central role in tumor growth, cell survival and 
activation of pro-survival signaling pathways, including the PI3K and MAPK cascades 
(Okegawa, et al. 2004 and Rodriguez, et al. 2012). We sought to determine the effect 
IGPR-1 has on survival and growth in microsatellite-stable (MSS) and microsatellite 
instability (MSI) CRC cell lines. We used HT29 cells as the MSS line; these cells have 
mutations in the APC and P53 genes (Comes, et al. 2007). HCT116 cells were chosen as 
the MSI cell line, and in addition to loss of expression of DNA mismatch repair genes, 
they contain mutations in β-catenin, KRAS and TGF-βIIR genes (Duldulao, et al. 2012 
and Comes, et al. 2007). A mouse B16F melanoma cell line was also used as a non-CRC 
control. All three of these cell lines express extremely low levels of IGPR-1 
endogenously, but overexpression of the molecule via retroviral vector transduction 
proved successful (Figure 2, A-C). 
IGPR-1 overexpression had a significant pro-survival effect on all three of these 
cell lines in a nutrient-poor, 3D culture system (Figure 2, A-C). Specifically, IGPR-1 
expression in HT29 cells was associated with an overwhelmingly positive trend in cell 
survival and growth, rather than the blunted, negative trend seen in HCT116 cells (Figure 
2, A-B). This suggests that IGPR-1 not only promotes increased HT29 cell survival, but 
also increased cell proliferation in a culture system that mimics anchorage-independence. 
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Figure 2: Overexpression of IGPR-1 promotes tumor cell survival. (A) HT29 cells 
expressing empty vector vs. IGPR-1 were subjected to a cell survival assay every 48 
hours as described in Materials and Methods. Cells expressing IGPR-1 showed a 
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significantly higher survival percentage after 4 days (*P<0.01). (B) HCT116 cells 
expressing empty vector vs. IGPR-1 were subjected to the same cell survival assay 
protocol. Cells expressing IGPR-1 died at a slower rate than cells expressing empty 
vector (*P<0.05; ^P<0.01). (C) Mouse B16F melanoma cells expressing empty vector or 
IGPR-1 were subjected to a cell survival assay that began on day 2 of incubation as 
described in Materials and Methods. Contrary to cells expressing empty vector, cells 
expressing IGPR-1 did not experience a drop in survival percentage after 6 days 
(*P<0.05). All graphs show means of a four-well experiment that was conducted in 
triplicate. All error bars denote one standard deviation from the mean of four wells. 
Chimeric IGPR-1 (cIGPR-1) Indicates that Activation of IGPR-1 Stimulates Tumor 
Growth 
 Prior work with IGPR-1 in PAE cells has demonstrated that stimulation of the 
molecule’s extracellular immunoglobulin domain via trans dimerization is required for it 
to regulate endothelial cell morphology and adhesion (Rahimi, et al. 2012). To determine 
whether IGPR-1 could be stimulated in a controlled manner in the absence of its wild-
type extracellular domain, we generated a chimeric IGPR-1 receptor containing the 
extracellular portion of the colony-stimulating factor-1 (CSF-1) receptor and the 
transmembrane and cytoplasmic domains of IGPR-1 (Figure 3A). This “chimeric IGPR-
1,” hereafter called cIGPR-1, is an inducible version of the molecule, the activation of 
which could theoretically be controlled via treatment with the CSF-1 ligand. 
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 After inducing cIGPR-1 expression in HT29 cells via a retroviral vector system, 
we treated cells in the 3D culture system with 0 ng, 10 ng or 50 ng of CSF-1. Subsequent 
assays performed at two and four days post-culturing demonstrated that IGPR-1 
promoted survival only in cells treated with either 10 ng or 50 ng of CSF-1 (Figure 3B). 
This result suggests that cIGPR-1 can only be activated if its extracellular domain is 
stimulated with the appropriate ligand; the intracellular portion of IGPR-1 is incapable of 
auto-stimulation. 
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Figure 3: cIGPR-1 is an inducible molecule that promotes CRC survival only in the 
presence of CSF-1. (A) The cartoon depicts an inducible version of IGPR-1 that was 
created by combining the extracellular domain of the CSF-1 receptor with the 
transmembrane and cytoplasmic domains of IGPR-1. This molecule was successfully 
cloned into a viral vector and expressed in HT29 cells. (B) HT29 cells expressing cIGPR-
1 promoted survival in a 3D culture system only after treatment with media containing 10 
ng or 50 ng of CSF-1 (
1
P<0.01; 
2
P<0.01). The graph shows means of a four-well 
experiment that was conducted in triplicate. All error bars denote one standard deviation 
from the mean of four wells. 
The Extracellular Immunoglobulin Domain is Required for IGPR-1 Activation 
To further explore the role that IGPR-1’s extracellular domain plays in the 
molecule’s activity, we cloned a soluble, myc-tagged version of IGPR-1’s extracellular 
domain, expressed it in human embryonic kidney (HEK-293) cells and collected it once it 
had been secreted in the cells’ media (Figure 4A). HT29 cells expressing empty vector 
vs. IGPR-1 were treated with either untreated serum-poor media or soluble IGPR-1 
(sIGPR-1)-enriched media. Cell survival assay findings showed that HT29 cells treated 
with sIGPR-1 proliferated dramatically and had significantly higher survival percentages 
than cells treated with control media (Figure 4B). This suggests that sIGPR-1 is capable 
of activating membrane-bound IGPR-1 via trans dimerization. This activation, when 
added to baseline IGPR-1 activity, has an additive effect on HT29 cell survival and 
proliferation. 
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Figure 4: IGPR-1 mediates its pro-survival effect via stimulation of its extracellular 
domain. (A) The cartoon depicts the structure of sIGPR-1 as compared to the original 
IGPR-1 molecule. sIGPR-1 production in HEK-293 cells’ media was confirmed via 
Western blot. (B) IGPR-1-expressing HT29 cells treated with media containing soluble 
IGPR-1 had a significantly higher growth rate than cells treated with normally 
conditioned media in a 3D culture system. HT29 cells expressing an empty vector also 
demonstrated a significant increase in growth upon treatment with soluble IGPR-1 (all 
numerals denote P<0.01 for the corresponding pairs of data points). (C) HT29 cells 
expressing ΔN-IGPR-1 were similar to cells expressing empty vector in terms of survival 
percentage (^P<0.05, †P<0.05, *P<0.01; data representative of two independent 
experiments). The graphs in (B) and (C) show means of four-well experiments that were 
conducted in duplicate. All error bars denote one standard deviation from the mean of 
four wells. 
 
We also wanted to investigate the effect that deletion of the immunoglobulin 
domain would have on IGPR-1’s activity in HT29 cells. We transduced HT29 cells with 
a viral vector containing an N-terminus-truncated version of IGPR-1 (ΔN-IGPR-1) that 
has 133 fewer amino acids than the native molecule (Rahimi, et al. 2012). Cells 
expressing ΔN-IGPR-1 had a stagnant survival pattern similar to what is seen in cells 
expressing an empty vector, while cells expressing IGPR-1 continued to survive and 
proliferate at a significantly higher rate (Figure 4C). Taken together with the cIGPR-1 
and sIGPR-1 data, this seems to suggest that stimulation of an extracellular domain, 
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regardless of whether or not it is the wild-type immunoglobulin domain, is essential for 
IGPR-1’s activation and subsequent pro-survival and pro-growth effects in HT29 CRC 
cells. 
Serine Residue 220 is Required for IGPR-1 Activity 
 Prior mass spectrometry analysis of IGPR-1 revealed several putative serine 
phosphorylation sites in the molecule’s cytoplasmic domain (Figure 5A). Since many 
membrane-bound receptors and adhesion molecules initiate their intracellular effects via 
protein phosphorylation, we investigated the effect that mutating two of these serine 
residues would have on IGPR-1’s functionality in HT29 CRC cells. Site-directed 
mutagenesis was used to create two mutant IGPR-1 molecules: one with a Ser-Ala point 
mutation at residue 220 and the other with the same point mutation at residue 186. These 
mutant IGPR-1 molecules were overexpressed in HT29 cells, and their growth and 
survival in the 3D culture system was assessed (Figure 5A). The cell survival assay 
showed that the point mutation at residue 220 caused a more dramatic drop in cell 
proliferation compared to the point mutation at reside 186, although it was still not as 
effective as the wild-type molecule at promoting cell growth (Figure 5B). This data 
suggests that phosphorylation of serine 220 is the cornerstone of IGPR-1’s intracellular 
signaling mechanism. 
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Figure 5: Serine phosphorylation mediates IGPR-1’s downstream effects in HT29 
cells. (A) Prior tandem mass spectrometry identified several putative serine 
phosphorylation sites in IGPR-1’s cytoplasmic domain. Subsequent site-directed 
mutagenesis created Ser-Ala point mutations at residues 220 and 186, and these mutated 
IGPR-1 molecules were successfully overexpressed in HT29 cells. (B) Cells expressing 
A220 mutant IGPR-1 experience stagnant growth, while cells expressing A186 mutant 
IGPR-1 do proliferate, albeit at a significantly lower rate than cells expressing wild-type 
IGPR-1 (*P<0.01, ^P<0.01, †P<0.05). The graph shows means of a four-well experiment 
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that was conducted in duplicate. All error bars denote one standard deviation from the 
mean of four wells. 
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DISCUSSION 
 This study demonstrated that IGPR-1, a novel cell adhesion molecule, promotes 
CRC cell growth and survival. This effect is dependent on both the activation of IGPR-1 
via its extracellular domain and the presence of specific serine residues in its cytoplasmic 
domain. Although many cell adhesion molecules have typically been associated with 
prevention of cancer progression, some have been identified as promoters of invasion and 
metastasis. Epithelial cell adhesion molecule (EpCAM) was recently associated with 
prostate cancer cell proliferation, invasion and metastasis via activation of the pro-
survival PI3K/Akt pathway. EpCAM knockdown was also associated with increased 
sensitivity to chemotherapeutic agents (Ni, et al. 2013). E-cadherin, though it is often 
regarded as the epithelial, anti-metastatic adhesion molecule associated with the EMT, 
has been implicated in the growth and survival of inflammatory breast carcinoma and 
glioblastoma. It has also been associated with pro-survival PI3K/Akt and MAPK 
signaling in a large number of ovarian cancers, which paradoxically express higher levels 
of E-cadherin than what is observed in normal ovarian tissue (Rodriguez, et al. 2012). 
IGPR-1 functions similarly in CRC by supporting cell growth and survival in an in vitro 
model that mimics anchorage-independent conditions. 
 Because cell adhesion molecules play an important role in cancer progression, 
they have garnered considerable interest as potential cancer biomarkers/therapeutic 
targets. EpCAM’s importance as a cancer stem cell marker and a promoter of metastasis 
has made it a popular biomarker candidate for breast and ovarian cancers. Studies have 
shown that serum levels of EpCAM were significantly elevated in patients with either 
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breast or ovarian cancer, but the molecule did not have any prognostic effect in both 
patient populations (Karabulut, et al. 2014 and Tas, et al. 2014a). EpCAM has also shown 
promise as an oncogenic marker that can be exploited to target epithelial cancers for drug 
delivery (Simon, et al. 2013). For example, a recent study showed that curcumin-loaded 
nanoparticles functionalized with EpCAM aptamers were able to bind HT29 CRC cells 
much more effectively than a control nanoparticle, and this resulted in significantly 
higher cytotoxicity (Li, et al. 2014). IGPR-1 could also be exploited in a similar manner 
to target proliferating CRC cells. 
Vascular cell adhesion molecule-1 (VCAM-1) has also garnered interest for its 
role as a potential marker of tumor invasion. While VCAM-1 had no diagnostic or 
prognostic value in breast cancer patients, it was found at higher levels in ovarian cancer 
patients with metastatic disease (Karabulut, et al. 2014 and Tas, et al. 2014a). VCAM-1 
levels were also elevated in lung cancer patients’ serum, and higher VCAM-1 content 
was associated with platinum-based chemotherapy unresponsiveness and lower survival 
rates (Tas, et al. 2014b). This suggests both a diagnostic and prognostic role for VCAM-1 
in lung cancer patients treated with a specific therapeutic regimen. Lastly, VCAM-1 was 
found to be significantly elevated in CRC patients’ serum, and it was associated with 
poor prognosis in these patients (Okugawa, et al. 2009). Although the question of 
whether IGPR-1 can be detected at appreciable levels in the serum of cancer patients 
remains unanswered, its role in CRC growth and survival is an encouraging sign for its 
potential as a diagnostic or prognostic marker. 
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 While the current study demonstrated a significant pro-growth and pro-survival 
effect in CRC cells expressing IGPR-1, it was limited by a lack of confirmation of these 
findings with another method such as flow cytometry. We also did not examine the effect 
of knocking down IGPR-1 in a CRC cell line that expresses it endogenously, but we have 
identified Colo205 cells as a candidate cell line for this purpose (data not shown). 
 In conclusion, we found that IGPR-1 is a cell adhesion molecule that promotes 
growth and survival when expressed in colorectal cancer cells. We also demonstrated that 
this effect is dependent upon both the activation of IGPR-1 via its extracellular 
immunoglobulin domain and the presence of the specific serine residue 220 in its 
cytoplasmic region. Future studies should investigate both the signaling mechanism by 
which IGPR-1 mediates its pro-growth and pro-survival effects in CRC cells and the 
effect IGPR-1 expression has on CRC tumor growth and metastasis in an in vivo mouse 
model. 
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